IONIQs breast cancer feasibility results published by IEEE
Salt Lake City, UT, November 30, 2021 - In collaboration with two of our Scientific Advisors, IONIQ Sciences, Inc. ("IONIQ" or the "Company"), is proud to announce the prestigious IEEE Access peer-reviewed journal has published a scientific manuscript on the life-saving potential of our 'breakthrough' bioimpedance technology in breast cancer.
Products & Services
IONIQ Pipeline - IONIQ Sciences
IONIQ Sciences
Our lung cancer and breast cancer tests are foundational on our quest to developing a Multi-Cancer Screen. We are well positioned to develop a multi-cancer screen by leveraging our lung test, breast test, proprietary technology, substantial EIA database, and our deep clinical experience. Not available for sale in the USA.
Platform Technology - IONIQ Sciences
IONIQ Sciences
The IONIQ System utilizes Electrical Impedance Analytics (EIA) to take up to 13,125 electrical readings of the body over a 20 minute period. Our proprietary algorithm processes this data to determine the likelihood of malignancy in its earliest, most-treatable stages.
')">
')" data-toggle="tooltip" data-placement="top" title="Share this with colleagues">
IONIQ Sciences Announces MedTech Breakthrough Award for "Oncology Innovation of the Year 2021"
IONIQ Sciences
IONIQ Sciences Announces MedTech Breakthrough Award for "Oncology Innovation of the Year 2021" Salt Lake City, UT, November 10, 2021 - IONIQ Sciences, Inc. ("IONIQ" or the "Company"), has been awarded the prestigious "Oncology Innovation of the Year 2021" by MedTech Breakthrough Awards.
Description
Salt Lake City, UT, November 30, 2021 - In collaboration with two of our Scientific Advisors, IONIQ Sciences, Inc. ("IONIQ" or the "Company"), is proud to announce the prestigious IEEE Access peer-reviewed journal has published a scientific manuscript on the life-saving potential of our 'breakthrough' bioimpedance technology in breast cancer.
